Increase a baby’s IQ 6+ points by… testing the embryo?
Below is a summary of the article I contributed to. Read the full article on MxLinx.
Heliospect Genomics, a U.S.-based biotech startup, offers trait selection in embryos, including IQ, physical attributes, and health risks, for $50,000 per 100 embryos.
Using data from the UK Biobank, Heliospect claims to aid IVF couples in selecting embryos based on traits like intelligence, height, and mental health risk.
Ethics and Regulation
In the U.S., embryonic screening for non-medical traits is largely unregulated, unlike the UK where selecting embryos for IQ is prohibited.
The technology sparks ethical debates about creating socioeconomic divides and whether genetic trait selection for non-medical attributes should be legal.
A 2024 JAMA survey found 75% of U.S. adults support embryonic screening for health traits, but many express concern over ethical risks and societal impacts.
Expert Insights on Social Impact
Thomas Kluz, a venture capital leader, notes that selecting for traits like IQ opens a “Pandora's box” of societal shifts. He foresees “compounded privilege,” where biological advantages intensify social inequality.
Kluz emphasizes the dangers of "feature creep," where health-focused selection could evolve into cosmetic or performance enhancements, potentially altering societal norms.
Psychological Implications
Rachel Goldberg, LMFT, PMH-C, underscores the psychological impact of trait selection, warning that children might feel pressured to meet genetic expectations, affecting self-worth and identity.
Goldberg highlights risks of reinforcing superiority and inferiority complexes, potentially reversing progress toward equality by promoting designer traits in children.
Future Concerns and Regulation
As genomic technology advances, experts like Goldberg argue for urgent regulation to manage the rapid development, emphasizing that unintended consequences could lead to lasting social disparities and psychological impacts.
